https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-11 08:42:022024-11-11 08:42:02STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-11 08:42:022024-11-11 08:42:02STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.
– Complete 3-year clinical data from the MATCH Phase 2 study…

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Infinitopes’ lead vaccine candidate ITOP1 is a novel, precision…

Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG…

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo…

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development
Brings over 30 years of experience in cardiovascular clinical…

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series…

Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe
Kling Biotherapeutics to Present Key Applications for its Primary…

Adcendo to Participate in Expert ADC Panel Debate at BIO-Europe 2024
Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”),…

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025
David Epstein, formerly CEO of Seagen, joins as Chair &…

Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG…

Novo Nordisk Foundation announces Denmark’s first AI supercomputer is now operational
New supercomputer built on NVIDIA DGX SuperPOD will accelerate…

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024
225Ac-Satoreotide is a first-in-class somatostatin receptor…

Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
Paris, France, October 22, 2024 – Vivet Therapeutics (“Vivet”),…

4SC publishes Q3 2024 report
Planegg-Martinsried, Germany, 17 October 2024 – 4SC AG (4SC,…

AMSilk Announces Successful Partnership Negotiation with Ajinomoto for Industrial Fermentation
Neuried, Germany, 16 October 2024: AMSilk GmbH (“AMSilk”/…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York